Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-beta-lactamase-producing strain of Pseudomonas aeruginosa.
about
Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosaIn vitro antimicrobial effects of aztreonam, colistin, and the 3-drug combination of aztreonam, ceftazidime and amikacin on metallo-beta-lactamase-producing Pseudomonas aeruginosaClonal diversity of metallo-beta-lactamase-possessing Pseudomonas aeruginosa in geographically diverse regions of JapanMetallo-beta-lactamases: the quiet before the storm?First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-beta-lactamase (VIM-2) in the United StatesMetallo-beta-lactamase or extended-spectrum beta-lactamase: a wolf in sheep's clothing.Carbapenemases: molecular diversity and clinical consequences.Metallo beta lactamases in Pseudomonas aeruginosa and Acinetobacter species.In vivo efficacy of humanized high dose meropenem and comparators against Pseudomonas aeruginosa isolates producing verona integron-encoded metallo-β-lactamase (VIM).Metallo-beta-lactamase-producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of JapanDissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia.Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.Extensively drug-resistant (XDR) identified in Lima, Peru co-expressing a VIM-2 metallo-β-lactamase, OXA-1 β-lactamase and GES-1 extended-spectrum β-lactamase
P2860
Q24612271-64B12C23-6DE4-4C4B-99DF-B3E2693A8B5BQ33491829-FFFF97D0-529F-4079-B23B-90BF8FF7DA27Q33592244-EE273D75-563E-4286-A842-750543FBA8B4Q33755227-1FA7AA1B-CD53-4545-8AB4-0AE3986AAAD3Q33938126-52E60D76-A14E-4207-A0C2-8E295625C03AQ35913952-61A953B6-6A50-47A1-B6F7-71F3755051FEQ36967241-858EE524-666B-411A-97FA-7CA5DF7AEE05Q37071179-3E2F5B74-1434-4FF9-9813-5E4996ED02C3Q37097371-F9649E93-079C-409B-94B2-7230338CF05BQ37597421-740928B2-1680-4997-BEAD-723BDA8C9117Q46788965-0722804F-17A2-4C8C-A457-04AFF1960B85Q47661746-2208981F-D229-4AD4-8541-1E17FC63158AQ57143529-F8F05824-4A44-499A-8B70-0B2677E2DCFB
P2860
Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-beta-lactamase-producing strain of Pseudomonas aeruginosa.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Efficacy of beta-lactams for t ...... ain of Pseudomonas aeruginosa.
@en
Efficacy of beta-lactams for t ...... ain of Pseudomonas aeruginosa.
@nl
type
label
Efficacy of beta-lactams for t ...... ain of Pseudomonas aeruginosa.
@en
Efficacy of beta-lactams for t ...... ain of Pseudomonas aeruginosa.
@nl
prefLabel
Efficacy of beta-lactams for t ...... ain of Pseudomonas aeruginosa.
@en
Efficacy of beta-lactams for t ...... ain of Pseudomonas aeruginosa.
@nl
P2093
P2860
P921
P1476
Efficacy of beta-lactams for t ...... ain of Pseudomonas aeruginosa.
@en
P2093
Anne Jacolot
Olivier Mimoz
Olivier Petitjean
Samuel Bellais
Sophie Léotard
P2860
P304
P356
10.1128/AAC.46.6.2032-2034.2002
P407
P577
2002-06-01T00:00:00Z